BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that updated data evaluating continuous treatment with REVLIMID® (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology. The study demonstrated that early treatment with lenalidomide and dexamethasone followed by continuous lenalidomide delayed time to symptomatic disease and demonstrated a projected survival advantage compared with observation.
